Company intelligence / Profile preview
TRACON Pharmaceuticals, Inc.
San Diego, California, USAtraconpharma.com ↗
- Ownership
- Public · TCON
- Employees
- ~20
- Development stage
- Phase 2
01
Overview
TRACON’s lead program envafolimab failed to meet its primary endpoint in the pivotal Phase II ENVASARC trial for refractory soft tissue sarcomas in July 2024 and all related development was discontinued. The company’s small molecule DNA repair inhibitor TRC102 showed activity in recurrent glioblastoma but remained investigational through NCI-sponsored trials. The company entered formal liquidation and dissolution by shareholder vote in November 2024.
- Therapeutic areas
- GastroenterologyOncologyOphthalmologyHematology
- Modalities
- Monoclonal antibodies (mAbs)Small moleculesBispecific antibodies (preclinical)
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
Request access →03
Partnerships
Janssen Pharmaceutica N.V. / J&J (for TRC253)National Cancer Institute/NCI CRADA partnership for multiple trials with TRC102Alphamab Oncology & Jiangsu Alphamab Biopharmaceuticals /3D Medicines Co., Ltd. (licensing envafolimab)Eucure Biopharma/Biocytogen/Eucure partnership on YH001I-Mab Biopharma collaboration on TJ004309/bispecifics
04
Financials
- Market cap
- $109.7K
- Total revenue
- $55K
- Enterprise value
- $-6.2M
Beyond the preview
Go deeper on TRACON Pharmaceuticals, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TRACON Pharmaceuticals, Inc..